The Board of Directors of the Company at its meeting held on August 01, 2025, has, inter alia, considered and approved the Unaudited Financial Results of the Company (Standalone andConsolidated), for the quarter ended June 30, 2025

Results restatedExceptional itemNet loss reportedResults View source PDF Explain this filing

HCG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.5%Reaction day

₹605.05

prior close

₹599.05

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.5%-0.0% vs market

Hospital peers, median of 18sector-0.2%+0.7% vs sector

On the reaction day the stock moved in line with Nifty Microcap 250 and 0.7 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

+1.2

15m

+2.7

30m

+2.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.5+0.5-0.0-0.2+0.7

Next day

+1.6+0.2+1.5+0.6+1.1

+1.3-0.9+2.2-0.5+1.8

+1.4-1.2+2.6-0.6+2.1

+1.2-2.0+3.3-1.8+3.0

+9.4-1.9+11.3-1.3+10.7

+12.7-1.2+13.9+2.2+10.5

15d

+14.0-1.5+15.5-1.4+15.4

+14.8+0.0+14.7-1.7+16.5

+8.6-0.5+9.1+2.8+5.8

+26.4+1.3+25.1-1.9+28.4

UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 18Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

HCG reported Q1 FY26 standalone revenue from operations of Rs. 32,593 lakhs (up ~3.9% from Rs. 31,360 lakhs in restated Q1 FY25), but profit before tax fell sharply to Rs. 179 lakhs from Rs. 1,276 lakhs, and the company recorded a net loss of about Rs. 206 lakhs after a tax outflow of Rs. 385 lakhs. Consolidated revenue grew ~16.6% to Rs. 61,180 lakhs, but consolidated PAT dropped to Rs. 598 lakhs (from Rs. 1,363 lakhs) and EPS fell to Rs. 0.34 from Rs. 0.87. The quarter included an exceptional loss of Rs. 155 lakhs and Rs. 157 lakhs in legal/professional fees for the KKR share purchase. Prior-year Q1 figures were restated to reflect a common-control business transfer with HCG NCHRI Oncology LLP.

Likely market impact

Weak operating quarter with margin compression and a standalone net loss, partly dragged by exceptional items and one-off transaction costs. Shareholders have a near-term price reference of Rs. 504.41 per share from the KKR-led mandatory open offer, while a major ownership shift to KKR (51.59% acquired on May 30, 2025) and Rs. 5,808 lakhs cash ESOP settlement could pressure near-term earnings but may improve long-term strategic direction.